Find a Clinical Trial

Filter

Services

Allergy

Allergy
Amyloidosis

Amyloidosis
Anesthesiology

Anesthesiology
Aortic Diseases + Aneurysms

Aortic Diseases + Aneurysms
Asthma

Asthma
Back + Neck Pain

Back + Neck Pain
Bladder Cancer

Bladder Cancer
Blood Disorders + Hematology

Blood Disorders + Hematology
Brain Tumor

Brain Tumor
Breast Surgery + Oncoplastics

Breast Surgery + Oncoplastics
Cancer

Cancer
Cardiac Sarcoidosis

Cardiac Sarcoidosis
Cardiac Surgery

Cardiac Surgery
Cardiology

Cardiology
Cardiology (Pediatrics)

Cardiology (Pediatrics)
Cardiovascular Care

Cardiovascular Care
Center for Children with Special Needs
Colon + Rectal Cancer

Colon + Rectal Cancer
Critical Care

Critical Care
Dentistry

Dentistry
Dermatology

Dermatology
Emergency Medicine (Pediatrics)

Emergency Medicine (Pediatrics)
Gastroenterology + Digestive Health

Gastroenterology + Digestive Health
Gastroenterology + Digestive Health (Pediatrics)
Gynecologic Cancer

Gynecologic Cancer
Gynecology (Pediatric + Adolescent)

Gynecology (Pediatric + Adolescent)
Head + Neck Cancer

Head + Neck Cancer
Heart Failure + Heart Transplant

Heart Failure + Heart Transplant
Hematologic Cancers

Hematologic Cancers
Hospital Medicine (Pediatrics)

Hospital Medicine (Pediatrics)
Infectious Diseases

Infectious Diseases
Inflammatory Bowel Disease (IBD)

Inflammatory Bowel Disease (IBD)
Interventional Cardiology

Interventional Cardiology
Kidney Function Evaluation

Kidney Function Evaluation
Liver Disease

Liver Disease
Lung Cancer

Lung Cancer
Maternal Fetal Medicine

Maternal Fetal Medicine
Multiple Sclerosis

Multiple Sclerosis
Myeloma + AL Amyloidosis

Myeloma + AL Amyloidosis
Nephrology

Nephrology
Nephrology (Pediatrics)

Nephrology (Pediatrics)
Neurology

Neurology
Neurosurgery

Neurosurgery
Newborn Medicine

Newborn Medicine
Obstetrics + Gynecology (OBGYN)

Obstetrics + Gynecology (OBGYN)
Obstetrics + Maternity

Obstetrics + Maternity
Ocular Melanoma

Ocular Melanoma
Ophthalmology (Pediatrics)

Ophthalmology (Pediatrics)
Ophthalmology + New England Eye Center
Orthopedics

Orthopedics
Orthopedics (Pediatrics)

Orthopedics (Pediatrics)
Orthopedic Trauma

Orthopedic Trauma
Osteoarthritis

Osteoarthritis
Otolaryngology — Head + Neck Surgery (Ear, Nose + Throat)
Pancreatic Cancer

Pancreatic Cancer
Pediatrics

Pediatrics
Prostate Cancer

Prostate Cancer
Psychiatry + Psychotherapy (Adult)

Psychiatry + Psychotherapy (Adult)
Pulmonary Hypertension

Pulmonary Hypertension
Pulmonology

Pulmonology
Radiation Oncology

Radiation Oncology
Rheumatoid Arthritis

Rheumatoid Arthritis
Rheumatology

Rheumatology
Spine Care

Spine Care
Stroke

Stroke
Stroke + Young Adults (SAYA)

Stroke + Young Adults (SAYA)
Surgery

Surgery
Thoracic Surgery

Thoracic Surgery
Trauma Surgery

Trauma Surgery
Urology

Urology
Valvular + Structural Heart Health

Valvular + Structural Heart Health
Vascular Disease

Vascular Disease
Vascular Surgery

Vascular Surgery
Wound Healing

Wound Healing
Breast Cancer

Breast Cancer
Cancer + Hematology (Pediatrics)

Cancer + Hematology (Pediatrics)
Tuberculosis + Other Mycobacterial Infections

Showing 1 - 10 out of 11

AN2 EBO301 MAC Study

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)

Mycobacterial disease

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Tufts Medical Center

Learn more

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)

A phase 3 randomized, open-label study of OP-1250 monotherapy vs standard of care for the treatment of ER+, HER2– advanced or metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy (OPERA-01)

Breast cancer, Locally advanced and metastatic breast cancer

All genders

18+

Recruiting now

Cancer Center

Tufts Medical Center

Learn more

HGB-210

A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease.

Sickle cell anemia

All genders

2-50

Recruiting now

Department of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

ANHL1931

ANHL1931: A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

Lymphoma

All genders

Recruiting now

Department of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

Breast Cancer Database

Breast cancer

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

All genders

18+

Recruiting now

Cancer Center

Tufts Medical Center

Learn more

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

Breast cancer

All genders

18+

Recruiting now

Cancer Center

Tufts Medical Center

Learn more

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

DESTINY BREAST - RESPOND: A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer (D9673R00025)

Breast cancer

All genders

16+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

HER2 Negative Breast Cancer

HCRN-BRE20-468 - A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

Breast cancer

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

Breast cancer

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

Language 1

Language 2

Language 3

Privacy on this site

We collect and process your data on this site to better understand how it is used. You can give your consent to all or selected purposes, or you can decline them all. For more information, see our privacy policy.

Analytics

Marketing automation

AnalyticsWe'll collect information about your visit to our site. It helps us understand how the site is used – what's working, what might be broken and what we should improve.

Marketing automationWe'll use your data to send you more relevant email or text message campaigns. We'll also use it to exclude you from campaigns that you might not like.

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)

A phase 3 randomized, open-label study of OP-1250 monotherapy vs standard of care for the treatment of ER+, HER2– advanced or metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy (OPERA-01)

A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease.

ANHL1931: A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

Breast Cancer Database

DESTINY BREAST - RESPOND: A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer (D9673R00025)

HCRN-BRE20-468 - A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy